Product Description
a novel myocardial implant for the treatment of acute myocardial infarction (MI). BL-1040 represents a breakthrough approach to supporting cardiac tissue damaged as a result of acute myocardial infarction (MI), improving cardiac function and survival. The novel myocardial implant is a resorbable liquid polymer that is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle. (Sourced from: https://ir.biolinerx.com/news-releases/news-release-details/biolinerxs-bl-1040-named-one-10-most-promising-cardiovascular)
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioLineRx
Company Location: MODI-IN L3 7177871
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Heart Rupture|Heart Failure, Chronic|Heart Block|Stroke|Heart Failure, Diastolic|Heart Failure, Systolic|Bradycardia|Kidney Diseases|Atrioventricular Block|Cardiac Arrhythmias
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00557531 | P2 |
Unknown status |
Kidney Diseases|Cardiac Arrhythmias|Heart Failure, Diastolic|Heart Failure, Chronic|Heart Failure, Systolic|Bradycardia|Heart Rupture|Stroke|Heart Block|Atrioventricular Block |
2010-01-01 |